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BRIEF REPORT
Chemotherapy Responsiveness in a Patient With Multiply Relapsed Ameloblastic
Fibro-Odontosarcoma of the Maxilla
Susanne A. Gatz, Dr. Med.,1* Khin Thway, MBBS, BSc, FRCPath,2 Henry Mandeville, MBChB, MRCP, FRCRMD(Res),3
Cyrus Kerawala, FDS, FRCS,4 David MacVicar, FRCP, FRCR,5 and Julia Chisholm, BM, BCh, PhD1
INTRODUCTION
Malignant odontogenic tumors are extremely rare entities,
occurring as carcinomas or sarcomas. Odontogenic sarcomas are
mixed tumors with two components: benign ameloblastic epithelium
and malignant fibrous stroma, with or without dentine and enamel.
The current 2005 WHO classification distinguishes two groups:
ameloblastic fibrosarcoma [AFS (9330/3)] (malignant fibrous tissue
with ameloblastic epithelium) and ameloblastic fibrodentino- and
fibro-odontosarcomas [AFOS (9290/3)] (with admixed dentine and
enamel, respectively).[1] Surgical excision is the accepted treatment.
Chemotherapy responses have been reported for selected cases of
AFS: one complete responsewas observed,[2] and two cases of good
response were consolidated by surgery and radiotherapy.[3]
AFOS is considered a low-grade tumor, possibly less aggressive
than AFS, with only one report of regional metastasis.[1] However,
recurrences and fatalities due to recurrence/progression involving
the skull base have been reported.[4,5] No data on chemotherapy in
AFOS exist.
CASE STUDY
An8-year-old femalewas referred to amaxillofacial surgeonwith a
right-sided facial mass involving the right maxillary antrum. Biopsy
suggested a hamartomatous complex odontoma. Curettage and
macroscopic tumor resection was performed with histology of the
resection specimen identical to the previous biopsy. Recovery was
uneventful and thepatientwas discharged from follow-up after 3 years.
Six years from initial presentation, the patient developed a painless
swelling lateral to the right maxillary antrum. A computerized
tomography (CT) scan showed a 3.7 3.4 cm soft tissue mass within
the rightmaxillawith bony destruction of the lateral and posterior wall
of the antrum. Debulking surgery with curettage was performed.
Histopathology revealed an AFOS with marginal involvement. The
patient was referred to our institution for further management.
Histopathological review of the resection specimens demonstrat-
ed that the initial tumor was a benign ameloblastic fibro-odontoma
(AFO) (Fig. 1AandB). The specimen at recurrence showed evidence
of malignant transformation to AFOS (Fig. 1C and D). The stromal
component showed greater cellularity, with loose fascicles of mildly
atypical spindle cells with a mitotic index of 5/10 high-power fields
(hpf). CT scans showed no evidence of residual local or pulmonary
metastatic disease (pT3a, N0, M0, IRS II A, grade 2). The patient
received radical intensity-modulated radiotherapy to the right
maxilla: 60Gy in 30 fractions over 6 weeks.
Four months after radiotherapy, surveillance magnetic resonance
imaging (MRI) revealed a 14mm 9mm ovoid lesion consistent
with a lymph node or possible tumor recurrence (Fig. 1E). An
ultrasound at the same time demonstrated a well-circumscribed
hypoechoic soft tissuemass. Therewas interval growthon ultrasound
scan 4 weeks later, when the patient presented with a further painless
swelling in her right temporal region, superior to the previous tumor
site and outside the radiation field. Biopsy confirmed relapse of
AFOS and pre-surgical CT demonstrated that the lesion was
gradually enlarging but did not show overt evidence of bony erosion.
Craniofacial resection of the mass was performed through combined
bicoronal and intraoral access, the former to allow excision of the
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Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare
malignant odontogenic tumor. Complete surgical excision is the
treatment of choice. Deaths due to disease recurrence and/or
progression are documented. Here, we report the case of a 15-year-
old female with multiple recurrent AFOS. She responded to
chemotherapy with ifosfamide and doxorubicin consolidated by
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stereotactic reirradiation using cyberknife and remained in complete 
remission 14 months from the end of reirradiation therapy. Chemo-
therapy with ifosfamide and doxorubicin should be considered in 
advanced cases of AFOS. Pediatr Blood Cancer
© 2015 The Authors. Pediatric Blood & Cancer Published by Wiley 
Periodicals, Inc.
2015;62:2029–2032. 
Published online 15 July 2015 in Wiley Online Library
Fig. 1. Histologic findings in theAFO andAFOS specimen and onMRI prior to first relapse. (A,B) Hematoxylin–eosin (HE) stained sections of the
initial tumor [ameloblastic fibro-odontoma (AFO)]. (A) Small islands and branching cords of ameloblastic epithelium are interspersed within
spindle cell stroma. The mesenchymal component is of moderate cellularity, but no pleomorphism is present and mitotic activity is low (up to 2/
10 hpf; magnification 100. (B) Other areas show odontogenic epithelium and dentine; magnification 40. (C,D) HE-stained section of the first
tumor recurrence [ameloblastic fibro-odontosarcoma (AFOS)]. (C) The prominence of the mesenchymal (spindle cell) component is apparent and
is of higher cellularity than the initial AFO; magnification 40. (D) The fascicular fibrosarcoma-like architecture of the spindle cell component is
discernible in areas, and only a small island of epithelium is seen here (top left). There is a focal mild atypia, and increased mitotic count of the
mesenchymal component (5/10 hpf); magnification 100. (E) Surveillance MRI 4 months after completion of radiotherapy for AFOS with
involved margins. T2-weighted sequence shows focal area of high signal (arrows) lying on lateral wall of right orbit, involving right temporalis
muscle. (F) HE-stained section of the first relapse of AFOS. The tumor shows more aggressive morphology, with prominent cellularity and
pleomorphism of the mesenchymal component, along with numerous mitotic figures (arrows) and a significantly increased mitotic index of 17/10
hpf. The tumor is seen to extensively infiltrate skeletal muscle fibres. The epithelial component is markedly reduced and is not seen in this field;
magnification 200.
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right temporalis muscle, and the latter to facilitate removal of the
right coronoid process of the mandible. The tumor was adherent to
the lateral skull base and as such, the lateral cortex of bone was
removed at this site to further secure clearance.
Histopathology indicated an increasingly aggressive recurrent
AFOS with increased cellularity, moderate pleomorphism, in-
creased mitotic index, and extensive infiltrative behavior (Fig. 1F).
Microscopic clearance was achieved at all but the medial margin at
the sphenoid bone but in view of the further shaving of the bone,
surgery was considered as complete.
Three months after surgery, the patient developed diplopia and
right periorbital swelling suspicious of second relapse ofAFOS.MRI
revealed a soft tissue mass arising from the right greater wing of
sphenoid measuring 4.0 3.3 cm. There was bony erosion through
the lateral wall of the right orbit with extension into the orbital fat and
intracranially into the right temporal fossa (Fig. 2A). Chemotherapy
with ifosfamide (3 g/m2 on days 1–3) and doxorubicin (37.5mg on
days 1 and 2) every 21 days was given for a total of six cycles without
dose reductions or significant delay. Therewas an immediate clinical
improvement in the swelling and normalization of the double vision
after three chemotherapy cycles. MRI performed after every two
cycles showed gradual partial response to treatment, most evident
after six cycles (Fig. 2B). The patient required hospital admissions
for antibiotic treatment of febrile neutropenia and pain management
for mucositis. Granulocyte-colony stimulating factor was given from
cycle 4 onwards. Subsequent cyberknife-based stereotactic ablative
radiotherapy was given to the site of recurrence, including overlap
with previous irradiation, delivering 42Gy in three fractions to the
72% isodose for consolidation. The patient remained free of disease
recurrence 14 months from completing cyberknife therapy, although
she experienced recurrent infection in the area receiving Cyberknife
reirradiation, probably related to radiation necrosis of bone.
DISCUSSION
AFOS is an extremely rare subtype of odontogenic sarcoma.
Seventeen cases have been reported in the literature to date.[1,6–9]
In contrast, although still rare, 66 cases of AFS had been published
in the literature in 2007 so that incidence, recurrence rate, and
histologic behavior are better understood.[6] With this report, we
contribute to better understanding of the rare disease entity of
AFOS and highlight the potential role of chemotherapy in its
management.
The following three major points from this case may help guide
clinicians in future similar cases:
Firstly, the AFOS in our patient developed on the background of
an AFO, which had initially been thought to represent a
hamartomatous complex odontoma. Our case highlights that
recurrence of swelling close to the initial site of AFO must raise
suspicion not only of recurrent AFO but also of malignant
transformation to AFOS. Up to one-third of AFS develop from
ameloblastic fibroma,[6,10] and there are three case reports of AFO
transforming to AFOS to date.[6,11] Our case supports this
etiologic sequence, and highlights that the possibility of malignant
recurrence must be considered in planning the follow-up of these
patients.
Secondly, AFS has been reported to become increasingly
aggressive clinically with each recurrence. The recurrence rate
overall is 37% and the disease is fatal in 20% due to locally
progressive disease.[10,12] The histopathological presentation can
change accordingly with each recurrence; AFS demonstrates
increasing evidence of stromal cellularity and mitotic activity but
diminishing evidence of odontogenic epithelium,[6] and we here
describe a similar observation in recurrent AFOS (Fig. 1).
Thirdly, and most importantly, the accepted treatment for AFOS
is surgical resection. However, recurrences and fatal cases due to
progression with involvement of the skull base have been reported
in at least two cases.[4,5] Although chemotherapy has been used
successfully in AFS.[2,3] there are no published data on
chemotherapy in AFOS. Given the unfavorable situation for our
patient, we opted to try chemotherapy with ifosfamide and
doxorubicin, a well-established combination for non-rhabdomyo-
sarcoma soft tissue sarcomas in children.[13] We demonstrate that
the tumor was responsive to this chemotherapy regimen, suggesting
Fig. 2. MRI findings prior to and after chemotherapy with ifosfamide and doxorubicin. (A) MRI findings of second relapse of AFOS: T2-weighted
MRI demonstrates a lobulatedmass returning high signal, at the site of resected tumor. Post-surgical baseline imaging less than 3months earlier had
shown no lesion at this site. Note that soft tissue penetrates into the middle cranial fossa and orbit (arrowheads). (B) Response to six cycles of
chemotherapy with ifosfamide and doxorubicin onMRI: T2-weightedMRI demonstrates resolution of the mass lesion (arrow). Some residual fatty
change is present. Cyberknife radiotherapy was subsequently administered to the tumor bed.
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that it would be appropriate to manage AFOS in children in the
same way as other high-grade non-rhabodomyosarcoma soft
tissue sarcomas using ifosfamide and doxorubicin treatment for
unresectable tumors, after resection of grade 3 tumors >5 cm, or
for tumors with locoregional spread (EpSSG NRSTS protocol,
NCT00334854. The chemosensitivity noted here supports a
possible role as neoadjuvant therapy to facilitate complete resection
in cases where resectionmay be difficult either at initial diagnosis or
in the event of recurrence.
In conclusion, AFOS is a rare tumor that may arise from AFO
and can show increasing aggressive features at successive
recurrences, and for which chemotherapy with ifosfamide and
doxorubicin may have a role in the adjuvant or neoadjuvant setting.
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NOTE ADDED TO THE PROOF
Subsequent to the preparation of this report the patient
developed progressive radiation necrosis of the right temporal
lobe which was noted on surveillance imaging. This was
successfully treated with 3 courses of 7.5mg/kg bevacizumab at
21 day intervals with stabilisation of the edema and high T2 signal
apparent on MRI.
The patient remains clinically asymptomatic and is in remission
at the primary site 2 years from the cyberknife treatment. However,
she has developed 3 small pulmonary nodules (maximum diameter
12mm), presumed to be metastatic lesions from the AFOS, which
have been treated with radiofrequency ablation. A tissue diagnosis
was not obtained. The appearance of presumed pulmonary
metastases may support the view that chemotherapy should be
considered at an early stage of treatment in AFOS.
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